FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0 5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Kovacs Shane William Charles				2. I <u>P</u> 7	2. Issuer Name and Ticker or Trading Symbol PTC THERAPEUTICS, INC. [PTCT]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify						
(Last) (First) (Middle) C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT					3. Date of Earliest Transaction (Month/Day/Year) 05/09/2017								X	Specify					
(Street) SOUTH PLAINF (City)			07080 (Zip)		4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - Nor	ı-Deriv	/ativ	e Se	curit	ies Ac	quired,	Dis	posed o	f, or Be	neficia	ally (Owned				
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		ar)	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)						5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) or (D) Pr		•	Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common	Stock			05/09	9/201	7			M		10,000	0 A	\$10	.85	37,	850		D	
		-	Table II -								osed of, onvertil				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,	4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year))	7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)		De Se	Price of erivative ecurity istr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amour or Number of Shares	er					
Stock Option (Right To Buy)	\$10.85	05/09/2017			М			10,000	(1)	(05/21/2023	Common Stock	10,00	0	\$0	45,625	5	D	
Stock Option (Right To Buy)	\$27.05								(2)	(01/27/2024	Common Stock	46,38	4		46,384	1	D	
Stock Option (Right To Buy)	\$51								(3)	(01/01/2025	Common Stock	85,60	0		85,600)	D	
Stock Option (Right To Buy)	\$30.86								(4)	(01/03/2026	Common Stock	80,00	0		80,000)	D	
Stock Option (Right To Buy)	\$11.23								(5)	(01/02/2027	Common Stock	52,50	0		52,500)	D	

Explanation of Responses:

- 1. This option award was granted on May 22, 2013, with 25% of the shares underlying the option vested on May 22, 2014, and an additional 2.083% of the original number of shares underlying the option vesting on a monthly basis thereafter, beginning on June 30, 2014.
- 2. This option award was granted on January 28, 2014, with 25% of the shares underlying the option vested on January 1, 2015, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 1, 2015.
- 3. This option award was granted on January 2, 2015, with 25% of the shares underlying the option vesting on January 1, 2016, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 1, 2016.
- 4. This option was granted on January 4, 2016, and vests over four years, with 25% of the shares underlying the option vesting on January 4, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 4, 2017.
- 5. This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.

Remarks:

/s/ Colleen Diver Johnson, attorney-in-fact

05/11/2017

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.